References
1. Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost. 2017;117(2):390–400.
2. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376(9757):2032–9.
3. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost. 2007;33(6):563–72.
4. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119 Suppl 1:176S-193S.
5. Allain JS, Gueret P, Le Gallou T, Cazalets C, Lescoat A, Jego P. La recherche de thrombophilie héréditaire et son impact thérapeutique dans la maladie thromboembolique veineuse : résultats d’une étude monocentrique rétrospective sur 162 patients. Rev Médecine Interne. 2016;37(10):661–6.
6. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for vte disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.
7. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35(43):3033–73.
8. Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax. 2013;68(4):391–3.
9. Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480‑3.
10. Nicolaides A, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, et al. Thrombophilia. Clin Appl Thromb. 2013;19(2):177–187.
11. Coppens M, Reijnders JH, Middeldorp S, Doggen CJM, Rosendaal FR. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost. 2008;6(9):1474–7.
12. Lapner ST, Kearon C. Diagnosis and management of pulmonary embolism. BMJ. 2013;346:f757.
13. Lim HY, Chua CC, Tacey M, Sleeman M, Donnan G, Nandurkar H, et al. Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data?: Venous thromboembolism management. Intern Med J. 2017;47(9):1034–42.
14. Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust. 2019;210(5):227–35.
15. Pernod G, Biron-Andreani C, Morange PE, Boehlen F, Constans J, Couturaud F, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc. 2009;34(3):156–203.
16. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J.2019;ehz405.
17. Sanchez O, Benhamou Y, Bertoletti L, Constant J, Couturaud F, Delluc A, et al. Recommendations of good practice for the management of thromboembolic venous disease in adults. Rev Mal Respir. 2019;36(2):249–83.
18. Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolys. 2016;41(1):129–43.
19. Shatzel JJ, O’Donnell M, Olson SR, Kearney MR, Daughety MM, Hum J, et al. Venous thrombosis in unusual sites: A practical review for the hematologist. Eur J Haematol. 2019;102(1):53–62.
20. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036.
21. Santamaria MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res. 2005;116(4):301–6.
22. Satpanich P, Rojnuckarin P. Risk factors for venous thromboembolism recurrences in Thai patients without cancer. Hematol Amst Neth. 2019;24(1):159‑65.
23. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–25.
24. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153(8):523–31. .
25. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168(15):1678–83.
26. Eichinger Sabine, Pecheniuk Natalie M., Hron Gregor, Deguchi Hiroshi, Schemper Michael, Kyrle Paul A., et al. high-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115(12):1609–14.
27. Zöller B, Ohlsson H, Sundquist J, Sundquist K. Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden. J Thromb Haemost. 2014;12(3):306–12.
28. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease. Chest. 2012;141 Suppl 2 :S419-S496.
29. Agrawal V, Kim ESH. Risk of recurrent venous thromboembolism after an initial episode: Risk stratification and implications for long-term treatment. Curr Cardiol Rep. 2019;21(4):24.
30. Albertsen IE, Nielsen PB, Søgaard M, Goldhaber SZ, Overvad TF, Rasmussen LH, et al. Risk of recurrent venous thromboembolism: A danish nationwide cohort study. Am J Med. 2018;131(9):1067-74.e4.
31. Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4(4):734–42.
32. Cohn DM, Vansenne F, de Borgie CA, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2012;12:CD007069.
33. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352–61.
34. Kudo M, Lee HL, Yang IA, Masel PJ. Utility of thrombophilia testing in patients with venous thrombo-embolism. J Thorac Dis. 2016;8(12):3697–703.
35. Di Minno MND, Ambrosino P, Ageno W, Rosendaal F, Di Minno G, Dentali F. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2015;135(5):923–32.
36. Sokol J, Timp JF, le Cessie S, van Hylckama-Vlieg A, Rosendaal FR, Kubisz P, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study. J Thromb Haemost. 2018;16(4):680–8.
37. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729–36.
38. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007;92(8):1107–14.
39. Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301(23):2472–85.
Author contributions: Baccouche H, Belhadj M and Said F designed the study and were involved in patient inclusion and results analysis. Belhadj M collected the clinical and laboratory data and was involved in statistical analysis. Baccouche H and Belhadj M wrote the paper. Said F, Naceur I, Ben Romdhane N and Houman MH revised the paper. Alls authors read and approved the final manuscript.
Aknowledgement: All authors would like to thank Pr Bachir Zouari for his precious help in statistical analysis
Conflict of interest: The authors declare that they have no conflict of interest
Funding: None
Figure 1 legend: During the study period, 300 patients were referred to the hematology department from the internal medicine department for IT screening. After exclusion of patients with missing clinical data, 190 patients were included in the evaluation of the impact of demographic and clinical characteristics on the risk of recurrence. Among these 190 patients, 94 patients with complete thrombophilia screening were appropriately followed up and were included in the study of the impact of IT screening on the risk of recurrence.